Arterial Calcifications: Causes, Risks, and Treatment

Arterial calcification is the buildup of calcium-phosphate mineral deposits in artery walls, and it develops through an active, cell-driven process rather than the passive “rusting of the pipes” it was once assumed to be. The condition takes different forms depending on where in the artery wall the deposits settle, and its consequences range from stiffened blood vessels and high blood pressure to heart attacks and limb amputations. Understanding the causes, risks, and available treatments requires recognizing that not all arterial calcification is the same, and that some widely used medications can make it worse.

Two Distinct Types of Arterial Calcification

Calcium deposits can form in two separate layers of the artery wall, and the distinction matters because the causes, the diseases they associate with, and the clinical consequences differ. Intimal calcification develops in the inner lining of the artery, within atherosclerotic plaques. It occurs alongside the fatty deposits, immune cells, and cholesterol buildup that characterize plaque disease.¹ Medial calcification, sometimes called Mönckeberg-type calcification, forms in the muscular middle layer of the artery and can exist independently of atherosclerosis entirely.²

The two types also favor different vessels. Intimal calcification tends to show up in large elastic arteries like the aorta and the coronary arteries. Medial calcification is more common in smaller muscular arteries, including those in the legs and feet. Many patients, particularly those with chronic kidney disease or diabetes, develop both types simultaneously, which complicates diagnosis and treatment. Because the modifying agents differ at each site (lipids drive intimal deposits while elastin fibers anchor medial ones), the biological triggers are not interchangeable, even though both end up producing the same mineral: hydroxyapatite.

How Artery Cells Turn Into Bone

The old view of arterial calcification was that calcium simply precipitated out of the blood and stuck to damaged tissue, the way limescite builds up inside plumbing. Research over the past two decades has overturned that idea. Calcification is now recognized as a regulated, cell-driven process in which vascular smooth muscle cells, the cells that normally contract to control blood flow, transform into cells that resemble the osteoblasts found in bone.³ Risk factors like high blood pressure accelerate this transformation: smooth muscle cells lose their contractile identity and begin expressing bone-forming genes instead.⁴

Adding to this process, cells under stress release tiny membrane-bound packages called extracellular vesicles. These vesicles cluster between collagen fibers in the vessel wall and serve as seeds for mineral crystal growth, essentially acting as nucleation sites where calcium and phosphate latch on and accumulate.⁵ Under healthy conditions the body holds this process in check with natural inhibitors. One of the most important is Matrix Gla protein, or MGP, which blocks mineral formation in soft tissues. MGP depends on vitamin K to become activated. When MGP is deficient or inactive, calcification accelerates.⁶

Why Kidney Disease Is the Biggest Accelerator

Chronic kidney disease stands out as the single strongest driver of arterial calcification. As kidney function declines, the body loses its ability to maintain a normal balance of calcium and phosphate. Phosphate accumulates in the blood and directly pushes smooth muscle cells toward their bone-like state, while elevated calcium triggers cell death and vesicle release. These two effects work together: when both calcium and phosphate are high, the combined stimulus is far greater than either one alone.⁷

Beyond the mineral imbalance, kidney disease introduces a cocktail of other promoters: uremic toxins, chronic low-grade inflammation, and oxidative stress, all of which tip the scale further toward calcification.⁸ In advanced kidney failure, inactive MGP levels in the blood predict how severe calcification will become, in both the intima and the media of the vessels.⁹

The most extreme consequence in kidney patients is calciphylaxis, a rare and life-threatening condition in which tiny arterioles in the skin calcify and clot, producing excruciating wounds and tissue death. Risk factors that come up repeatedly include low albumin, elevated alkaline phosphatase, diabetes, higher body weight, female sex, and the use of vitamin K-blocking blood thinners.¹⁰ Infections from these wounds make calciphylaxis lethal in a significant number of cases.¹¹

What Calcified Arteries Do to Blood Pressure and Organs

Healthy arteries are elastic. They expand with each heartbeat and recoil between beats, smoothing the pulse of blood flow so that organs receive steady perfusion. Calcified arteries lose that elasticity. The result is isolated systolic hypertension, where the top blood pressure number climbs while the bottom number stays normal or even drops. This pattern is extremely common in older adults and is recognized as a major consequence of medial arterial calcification.¹²

The heart pays a steep price. Stiffened arteries increase the workload on the left ventricle with every beat. In hemodialysis patients, calcification has been identified as the single most important contributor to left ventricular thickening, a structural change that raises the risk of heart failure.¹³

In the legs, the consequences are equally serious. Medial calcification in peripheral arteries correlates independently with higher rates of amputation and death among patients with peripheral artery disease.¹⁴ Calcification was an independent predictor of worsening limb ischemia even after researchers accounted for the extent of vessel blockage and standard cardiovascular risk factors like smoking and diabetes duration.¹⁵ An added problem: medial calcification was historically thought to avoid narrowing the vessel lumen, but accumulating evidence shows that heavy medial deposits can deform the artery wall inward, cause tissue overgrowth beneath the lining, and ultimately reduce blood flow after all.¹⁶

Measuring Calcification and Predicting Risk

The most established way to quantify arterial calcification is the coronary artery calcium (CAC) score, obtained from a low-dose CT scan of the heart. A CAC score of zero is reassuring; higher numbers indicate increasing plaque burden. Across multiple population-based studies with follow-up periods of up to fifteen years, the CAC score has proven to be a consistent, reproducible predictor of heart attacks, strokes, and cardiovascular death. It is especially useful in people without symptoms, helping to decide whether preventive therapies like statins are worthwhile.¹⁷

There are limits, though. CAC scoring detects established, macroscopic calcium. It cannot distinguish between stable, dense calcification and the early, active microcalcification that may signal a vulnerable plaque about to rupture. A newer imaging approach uses a radioactive tracer, ¹⁸F-sodium fluoride, combined with PET scanning. The tracer binds selectively to tiny, actively forming calcium crystals within plaques, allowing doctors to visualize calcification that is happening right now rather than calcium that settled years ago.¹⁸ In longitudinal studies, higher tracer uptake predicted the future appearance of new coronary calcium deposits on CT, suggesting the technique can catch calcification at a stage when intervention might still slow it down.¹⁹

An unexpected screening opportunity is emerging in women. Calcification in the breast arteries, routinely visible on mammograms, has been linked to cardiovascular outcomes. In postmenopausal women, the presence of breast arterial calcification was associated with roughly a fifty percent higher risk of atherosclerotic cardiovascular events, even after adjusting for traditional risk factors.²⁰ Because millions of mammograms are performed each year, automated AI-based measurement of breast arterial calcification could offer a low-cost addition to cardiovascular risk assessment without requiring any extra tests.²¹

The Statin Paradox

If you have been told your CAC score went up after starting a statin, you are not alone, and the explanation is counterintuitive. Statins reduce cardiovascular events by stabilizing plaques and lowering cholesterol, yet multiple studies show they simultaneously increase the amount of calcium visible on CT scans. The mechanism appears to involve two things: statins promote the healing of inflamed plaques by shifting immune cells toward an anti-inflammatory state, and this healing process itself drives mineralization. Statins also activate certain bone-forming signaling pathways in smooth muscle cells, further encouraging calcium deposition within the plaque.²²

This is where the paradox resolves. Dense, stable calcium within a plaque may actually be a sign of healing rather than danger. A heavily calcified plaque with a thick cap is far less likely to rupture and cause a heart attack than a soft, lipid-rich plaque with scattered microcalcification. One analysis found that statin-driven increases in HDL cholesterol partially offset the statistical link between statin use and higher CAC scores, suggesting the net cardiovascular effect remains protective even as the calcium number climbs.²³ The practical takeaway: a rising CAC score during statin therapy does not mean the drug is failing. Serial CAC scoring to monitor statin effectiveness can be misleading.

Warfarin, Vitamin K, and a Preventable Cause

Warfarin, one of the most widely prescribed blood thinners, works by blocking vitamin K recycling in the liver to reduce blood clotting. The problem is that the same vitamin K recycling pathway operates in artery walls, where it activates MGP, the natural calcification inhibitor. When warfarin shuts that pathway down, MGP remains inactive and unable to do its protective job. In animal models, warfarin markedly increased calcium concentrations across multiple arteries, with some vessels showing calcium levels up to twenty-fold higher than controls.²⁴ In humans, warfarin use is an established risk factor for calciphylaxis and is consistently identified in clinical reviews of the condition.¹⁰

The flip side is encouraging. In the same animal experiments, supplementing with high-dose vitamin K1 dramatically increased tissue vitamin K levels and blunted the development of calcification.²⁴ Vitamin K promotes MGP activation through a carboxylation step that is essential for the protein to bind and neutralize calcium crystals.²⁵ This has raised an obvious clinical question: should patients on warfarin be switched to newer anticoagulants that do not interfere with vitamin K? Many nephrologists now lean in that direction for kidney patients, though the decision depends on the individual’s clotting risk. The MGP-vitamin K connection also underpins MGP and Gas-6, two vitamin K-dependent proteins critical for vascular protection, both of which lose function during warfarin use.²⁶

Treatment Options Under Investigation

No drug is approved to reverse established arterial calcification outright, but several are being tested to slow its progression. Sodium thiosulfate, an inorganic compound already used for cyanide poisoning and some skin conditions, has been the most studied candidate. In hemodialysis patients, intravenous sodium thiosulfate slowed the rise in coronary and iliac artery calcium scores compared to untreated controls, and it reduced the progression of arterial stiffness as measured by pulse wave velocity.²⁷ In animal studies, the compound prevented aortic calcification in uremic rats, likely by boosting calcium excretion through the urine.²⁸

The enthusiasm comes with important caveats. In a meta-analysis focused on calciphylaxis specifically, sodium thiosulfate did not produce statistically significant improvements in skin lesion healing or survival compared with other approaches.²⁹ The animal data also flagged a concern: thiosulfate weakened bones in treated rats, raising the possibility of trading one problem for another.²⁸

A newer agent, SNF472, takes a different tack. Rather than flushing calcium from the body, it binds directly to hydroxyapatite crystals and blocks further crystal growth. In the CALIPSO trial of hemodialysis patients, those receiving SNF472 saw their coronary calcium scores rise by roughly half as much as the placebo group over the trial period.³⁰ The benefit was consistent across patient subgroups. Lab work confirmed the mechanism: SNF472 physically adsorbs onto the mineral surface and prevents additional crystallization.³¹

When calcification has already stiffened an artery to the point where a stent cannot be placed safely, procedural tools exist to physically break up the mineral. Intravascular lithotripsy uses sound waves delivered inside the artery through a catheter-mounted balloon, cracking the calcium so the vessel wall becomes compliant enough for a stent to expand properly.³² The approach has been validated in both coronary and leg arteries, where it facilitates endovascular treatment in vessels that calcification would otherwise make untreatable.³³

Calcium Supplements and the Question of Self-Inflicted Risk

Many older adults take calcium supplements for bone health, and a reasonable worry is whether those extra calcium ions end up in the wrong place. The concern is not hypothetical. Elevated calcium in the blood, even within the normal range, has been associated with more calcified coronary plaque, and lab studies show that high calcium concentrations directly push smooth muscle cells toward mineralization.³⁴ Healthy kidneys have a limited capacity to dump excess calcium, and that capacity shrinks with age and any degree of reduced kidney function.³⁵

The observational and trial evidence is mixed but leans cautious. Some studies of calcium supplementation have suggested cardiovascular harm, while others have not. The consensus position from cardiology reviews is that calcium intake should come primarily from food rather than pills, and that supplementation should be used only when dietary intake falls short of recommended levels.³⁶ The spike in blood calcium that follows swallowing a supplement tablet is much steeper than the gradual absorption from food, which may explain why pills carry a different risk profile than dietary calcium at similar total intakes.

Genetic Causes and the Gut Microbiome

Most arterial calcification develops over decades and reflects the cumulative burden of aging, metabolic disease, and lifestyle. But when severe calcification appears in young people, a hereditary disorder is often the explanation. A handful of rare single-gene conditions cause early-onset vascular calcification. These fall into categories based on what the faulty gene does: some disrupt the body’s production of pyrophosphate (a mineral inhibitor that prevents crystals from forming), others involve overactive inflammatory signaling, and one, Gaucher disease, involves lipid storage in cells.³⁷ One such condition, ACDC, results from mutations that impair an enzyme responsible for generating adenosine. Patients develop progressive calcification of leg arteries, sometimes requiring surgery for limb ischemia at a young age.³⁸

On a completely different front, researchers are finding connections between the gut microbiome and arterial calcification. Short-chain fatty acids, particularly propionate, produced by intestinal bacteria during fiber digestion, correlated negatively with calcification scores in a clinical cohort. When propionate was given to animals with experimentally induced calcification, it reshaped the gut microbiome, strengthened the intestinal barrier, reduced systemic inflammation, and lessened vascular calcium deposits.³⁹ These findings are early-stage, but they suggest that diet quality, specifically fiber intake, may influence calcification through microbial metabolites in addition to its well-known effects on cholesterol and blood pressure.

Arterial Calcification in Ancient Humans

It would be comforting to blame modern diets and sedentary lifestyles for all arterial calcification, but the archaeological record complicates that story. CT scans of fifty-two ancient Egyptian mummies revealed identifiable cardiovascular structures in most, and nearly half of those had definite or probable atherosclerotic calcification. Calcium deposits were found in the aorta, coronary arteries, carotid arteries, and leg vessels.⁴⁰ The mummies studied tended to come from higher social strata, which may reflect dietary factors unique to the ancient elite, but the finding still shows that arterial calcification long predates processed food, trans fats, and office chairs. It may be that vascular calcification is, to some extent, an inherent feature of arterial aging in humans, amplified but not created by modern risk factors. The practical implication is that prevention is about managing risk rather than expecting to eliminate calcification entirely.